1 min read
China has become a major destination for global clinical development, and one reason is its 60-day silent approval mechanism for clinical trials.
Introduced as part of China’s drug Regulatory reforms and outlined under the National Medical Products Administration (NMPA) framework, this mechanism allows sponsors to begin clinical trials if regulators do not raise objections within 60 working days after accepting a Clinical Trial Application (CTA).
In simple terms: no news can mean approval.
Instead of waiting for a formal approval letter, sponsors can proceed with their trial once the 60-day review window closes, provided the Center for Drug Evaluation (CDE) has not issued a rejection, request for major clarification, or clinical hold.
How Does It Work?
Here’s the typical process:
- Sponsors submit a CTA to China’s CDE
- The application undergoes an acceptance review
- Regulators assess clinical, non-clinical, and CMC data
- If no objections are issued within 60 working days, the trial is automatically considered approved
This model significantly reduces administrative delays compared to traditional approval systems that require explicit authorization before trials can begin.
Why It Matters for Drug Developers
The mechanism has helped China become a faster and more attractive market for:
- First-in-human studies
- Global multi-regional clinical trials (MRCTs)
- Oncology and rare disease development
- Faster patient recruitment
According to the National Medical Products Administration, the policy has already reduced average review timelines to approximately 50 working days, helping innovative therapies reach patients faster.
What’s New? China’s 30-Day Expedited Pathway
In 2025, China introduced an additional 30-day review pathway for eligible innovative drugs.
This accelerated route applies to:
- Pediatric drugs
- Rare disease treatments
- National priority innovative products
- Global synchronized development programs
Sponsors must demonstrate trial readiness and commit to initiating studies within 12 weeks of approval. If technical issues arise, applications may revert to the standard 60-day timeline.
Key Challenges for Sponsors
While timelines are faster, success still depends on:
- Strong CTA documentation
- China-specific regulatory strategy
- Ethics approvals
- Site readiness
- Compliance with local requirements
Incomplete submissions can still delay approvals.
Accelerate Clinical Development in China with Expert Support
Navigating China’s evolving clinical trial regulations requires local expertise. From CTA preparation and regulatory submissions to clinical trial strategy and compliance support, Freyr Solutions helps life sciences companies accelerate approvals and enter China with confidence.
Get in touch with our experts to streamline your China clinical trial journey.